/
Oncology
Metastatic Prostate Cancer
66
Pipeline Programs↗
60
Active Trials↗
39
Companies Involved↗
Metastatic Prostate Cancer is a moderately active landscape with 66 programs across 39 companies. The most active players are AstraZeneca, Sinotau Pharmaceutical Group, T.O.A.D. Oncology SA. 21 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 15
Phase 225
Phase 321
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
51 of 59 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 59 classified programs, each share of the total. Modality classified for 95% of 66 pipeline programs.
Analysis
Trial Status
265
clinical trials
Completed145 · 55%
Terminated38 · 14%
Recruiting36 · 14%
Active, not recruiting18 · 7%
Unknown status16 · 6%
Not yet recruiting6 · 2%
Other6 · 2%
Clinical Trials
Trial Activity
265 trials
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)